Company logo

ADMA Biologics | Sustainability Performance

https://www.admabiologics.com

This company develops and commercializes specialty plasma-derived biologics, focusing on therapeutic treatments for immunodeficient patients. It operates in the biopharmaceutical sector, emphasizing patient needs.

2004

United States

501 - 1,000 employees

Biotechnology

$500M - 1B in revenue

$100M - 500M in profitability

Sustainability Ranking & Industry Benchmark

#7337
Overall
#1595
in United States
#162
in Biotechnology

Sustainability Maturity


Sustainability Intent

Available in
Scale package

Access

Industry Rank

85 out of 243

Overview
Environmental
Digital emissions
Financial Data
Business performanceCapital & innovationAnalyst projections
Market cap Total market value of the company's outstanding shares, calculated by multiplying the share price by the number of shares outstanding.
1.8B$, 2026170.9% YoY
Revenue Total revenue reported in the company's financial statements for the specified reporting year, reflecting income generated from primary business activities. Expressed in millions of USD.
510.0M$, 202516.5% YoY
R&D intensity Research and development expenditure expressed as a percentage of revenue, reflecting the company's relative investment in innovation.
0.78%2025

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Sustainability employees

We follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.

Total sustainability employees

4-6

This value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.


    Available in
    Scale package

    Access